E
Humacyte, Inc. HUMA
$3.07 $0.0551.83%
Recommendation
Sell
Prev Close
$3.01
Volume
426,597
Avg Vol (90D)
3,738,617
Market Cap
$387.29M
Dividend & Yield
--
52-Week Range
$2.75 - $9.97
P/E (TTM)
--
EPS (TTM)
-$1.34
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Weak
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Humacyte's (HUMA) Buy Rating Reiterated at HC Wainwright
3/13/2025 - MarketBeat
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
3/12/2025 - Zacks Investment Research
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Average Price Target from Brokerages
3/11/2025 - Ticker Report
Humacyte price target lowered to $7.50 from $10 at TD Cowen
3/10/2025 - TipRanks Financial Blog
Humacyte price target lowered by $2.50 at TD Cowen, here's why
3/10/2025 - The Fly
Humacyte announces publication of Budget Impact Model for Symvess
3/10/2025 - The Fly
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
3/10/2025 - Globe Newswire
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)
3/8/2025 - MarketBeat
Humacyte (HUMA, $3.09) RSI Indicator left the oversold zone on March 07, 2025
3/8/2025 - Tickeron - Technical Analysis
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
3/7/2025 - Zacks Investment Research
Trestle Bio Announces Research Collaboration with Humacyte
3/6/2025 - GuruFocus
Humacyte, Trestle Biotherapeutics announce research collaboration
3/6/2025 - The Fly
Trestle Bio Announces Research Collaboration with Humacyte
3/6/2025 - Business Wire
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
3/5/2025 - Zacks Investment Research
Humacyte (HUMA, $3.2) RSI Indicator left the oversold zone on March 04, 2025
3/5/2025 - Tickeron - Stocks
Humacyte (HUMA, $3.06) RSI Indicator left the oversold zone on March 03, 2025
3/4/2025 - Tickeron - Stocks
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
3/3/2025 - Globe Newswire
Humacyte's (HUMA) "Buy" Rating Reiterated at Benchmark
2/28/2025 - MarketBeat
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
2/27/2025 - Zacks Investment Research
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
2/27/2025 - GuruFocus
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
2/27/2025 - Globe Newswire
Humacyte shares rise after patent for bioengineered human tissues manufacturing
2/27/2025 - Seeking Alpha - Healthcare
Humacyte shares rise after patent for bioengineered human tissues manufacturing
2/27/2025 - SeekingAlpha.com: All News
Humacyte announces issuance of U.S. patent covering Symvess manufacturing
2/27/2025 - The Fly
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess and Other Bioengineered Tissues
2/27/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$105.28M
EBIT (TTM)
-$112.49M
Net Income (TTM)
-$152.87M
Balance Sheet
Total Assets (Q)
$114.76M
Total Debt (Q)
$79.64M
Total Liabilities (Q)
$178.49M
Book Value Per Share (Q)
-$0.5317
Cash Flow
Cash from Operations (TTM)
-$90.60M
Cash from Investing (TTM)
-$1.66M
Cash from Financing (TTM)
$62.84M
Net Change in Cash (TTM)
-$29.42M
Filings
Filing Date
Friday, November 8, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
0.48
7-Day Total Return
-0.81%
30-Day Total Return
-28.72%
60-Day Total Return
-19.24%
90-Day Total Return
-39.55%
Year to Date Total Return
-40.83%
1-Year Total Return
-12.68%
2-Year Total Return
14.37%
3-Year Total Return
-52.03%
5-Year Total Return
--
52-week Low
Mar 13, 2025 - $2.75
52-week High
May 31, 2024 - $9.97
Valuation
Market Cap
$387.29M - Small Cap
Enterprise Value
$446.36M
Price/Sales (TTM)
--
Price/Book (Q)
-5.66
Dividends and Shares
Shares Outstanding
119.41M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.humacyte.com
Phone Number
919 313 9633
Address
2525 East North Carolina Highway 54
Durham, NC 27713
Country
United States
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic... more
NASDAQ 03/18/2025 10:41AM Eastern Quotes delayed
Weiss Ratings